Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
Saved in:
| Title: | Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. |
|---|---|
| Authors: | Shah, Manish A. (AUTHOR), Wainberg, Zev A. (AUTHOR), Catenacci, Daniel V. T. (AUTHOR), Hochster, Howard S. (AUTHOR), Ford, James (AUTHOR), Kunz, Pamela (AUTHOR), Lee, Fa-Chyi (AUTHOR), Kallender, Howard (AUTHOR), Cecchi, Fabiola (AUTHOR), Rabe, Daniel C. (AUTHOR), Keer, Harold (AUTHOR), Martin, Anne-Marie (AUTHOR), Liu, Yuan (AUTHOR), Gagnon, Robert (AUTHOR), Bonate, Peter (AUTHOR), Liu, Li (AUTHOR), Gilmer, Tona (AUTHOR), Bottaro, Donald P. (AUTHOR) |
| Source: | PLoS ONE. 12/23/2021, Vol. 16 Issue 12, p1-1. 1p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
